10:43 AM EDT, 08/13/2025 (MT Newswires) -- CEL-SCI ( CVM ) said Wednesday a breakthrough medicine designation application has been filed for head and neck cancer immunotherapy Multikine by an undisclosed Saudi Arabian pharmaceutical firm with the Saudi Food and Drug Authority.

CEL-SCI ( CVM ) signed a memorandum of understanding with the Saudi Arabian firm for the commercialization of Multikine in the country, and a final partnership agreement is expected in Q3, the company said.

If the application is approved, the therapy would immediately become available for sale in Saudi Arabia, the company added.

The response time for the application is about 60 days, CEL-SCI ( CVM ) said, citing the health regulator.

Price: 7.32, Change: -0.31, Percent Change: -4.04